Psöriazis ve Tüberküloz Konulu Yayınların Analizi

Year 2024, , 8 - 14, 29.02.2024

Mustafa Serhat Şahinoğlu , İrem Şahinoğlu , Sevil Alkan

https://doi.org/10.54005/geneltip.1259435

Abstract

Amaç: Psöriazis, sistemik etkileri olan ve dünya çapında nispeten yaygın bir inflamatuvar hastalıktır ve psöriazis tedavisi son yıllarda hızla ilerlemiştir. Bununla birlikte, mevcut tedaviler, özellikle de anti tümör nekroz faktörü (TNF) tedavileri tüberküloza yol açabilir.
Bu çalışmanın amacı, 1970-2021 yılları arasında yayınlanan tüberküloz ve psoriasis ile ilgili literatürü bibliyometrik teknikler kullanarak analiz etmekti.
Yöntemler: Bu bibliyometrik analiz çalışmasında, 1970-2021 yılları arasında yayınlanan psöriazis ve tüberküloz ile ilgili makaleleri bulmak için Web of Science veri tabanı kullanıldı. VOSviewer yazılım programı, ortak atıf, ortak yazarlık, ortak oluşum ve anahtar kelime analizini içeren görselleştirme bilgi haritaları oluşturmak için kullanıldı.
Bulgular: Web of Science veri tabanında psöriazis ve tüberküloz konusunda toplam 127 belge indekslenmişti. İlk yayınlar 1971'deydi, ancak 2004 yılına kadar başka yayın yoktu. 2010 yılından itibaren yayın sayısı artmaya başlamıştı. Yayınların çoğu araştırma makalesi idi (%49,606) ve bunların %91,339'u Science Citation Index Expanded indeksli dergilerde yayınlanmıştı. Psöriazis ve tüberküloz literatürüne 36 ülkeden 576 yazar katkıda bulunmuştu. Amerika Birleşik Devletleri (n=26), İtalya (n=21), İspanya (n=12) yayın sayısında ilk 3 ülke olmuştu. Makalelerin çoğu Dermatoloji (n=93, %73) ve Romatoloji (n=11, %9) araştırma alanlarındandı.
Sonuç: Psöriazis ve tüberküloz üzerine yapılan bu güncel çalışmadan da anlaşılacağı üzere özellikle anti-TNF tedaviler ile daha popüler hale gelmiştir. Bu çalışma, özellikle anti-TNF tedavisi alan psoriasis ve psoriatik artrit hastalarında tüberküloza daha fazla odaklanılmasını önermektedir.

Keywords

Bibliyometrik analiz, Psöriazis, Yayınlar, Tüberküloz, Anti-TNF

Analysis of Publications on Psoriasis and Tuberculosis

Abstract

Background: Psoriasis is a relatively common inflammatory disease globally with systemic implications and the treatment of psoriasis has advanced rapidly in recent years. However, current treatments, especially anti tumor necrosis factor (TNF) treatments, can lead to tuberculosis.
Objectives: This study's objective was to analyze tuberculosis and psoriasis-related literature that was published between 1970 and 2021 by using scientometric techniques.
Methods: In this bibliometric analysis study, the Web of Science database was used to find the articles on psoriasis and tuberculosis that were published between 1970 and 2021. The VOSviewer software program was used to generate visualization knowledge maps including co-citation, co-authorship, co-occurrence, and keyword analysis.
Results: A total of 127 documents in the field of psoriasis and tuberculosis were indexed in the Web of Science database. The first reports were in 1971, but until 2004 there was no other publications. Since 2010 the number of publications started to increase. The most of the publications were articles (49.606%) and 91.339% of them were published in Science Citation Index Expanded indexed journals. 576 authors contributed to psoriasis and tuberculosis literature from 36 countries. The United States (n=26), Italy (n=21), Spain (n=12) were the first 3 countries in the number of publications. The most of the articles were from Dermatology (n=93, 73%) and Rheumatology (n=11, 9%) research areas.
Conclusion: As can be understood from this current study on psoriasis and tuberculosis, it has become more popular, especially with anti-TNF treatments. This study recommends focusing more on tuberculosis, especially in psoriasis and psoriatic arthritis patients receiving anti-TNF therapy.

Keywords

Bibliometric analysis, Psoriasis, Publications, Tuberculosis, Anti-TNF

References

• World Health Organization, Global Tuberculosis Report-2013, WHO; Geneva, Switzerland, 2013. Accessed date: 01 July 2022. Avaliable from: https://apps.who.int/iris/handle/10665/91355
• Lange C, Dheda K, Chesov D, Mandalakas AM, Udwadia Z, Horsburgh CR Jr. Management of drug-resistant tuberculosis. Lancet. 2019;394(10202):953-66.
• WHO Global Tuberculosis Report 2020. Accessed date: 01 July 2022. Avaliable from: https://www.who.int/news/item/14-10-2020-who-global-tb-progress-at-risk
• WHO. Tuberculosis. Acces date: 20 July 2022. Avaliable from: https://www.who.int/health-topics/tuberculosis#tab=tab_1
• Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13(10):e1002152.
• Emery JC, Richards AS, Dale KD, McQuaid CF, White RG, Denholm JT et al. Self-clearance of Mycobacterium tuberculosis infection: implications for lifetime risk and population at-risk of tuberculosis disease. Proceedings of the Royal Society B. 2021;288(1943):20201635.
• Behr MA, Edelstein PH, Ramakrishnan L. Is Mycobacterium tuberculosis infection life long? BMJ. 2019;367:l5770.
• Taylor Z, Nolan CM, Blumberg HM. American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep. 2005;54:1–81.
• Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis- time for a paradigm change. J Eur Acad Dermatol Venereol. 2021;35(4):824-34.
• Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-94.
• Kurd SK, Gelfand JM: The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2009; 60(2): 218–24.
• Villani AP, Rouzaud M, Sevrain M, Barnetche T, Paul C, Richard MA et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. 2015; 73: 242-8.
• Dominguez-Rosado I, Moutinho V Jr, DeMatteo RP, Kingham TP, D’Angelica M, Brennan MF. Outcomes of the Memorial Sloan Kettering Cancer Center International General Surgical Oncology Fellowship. J Am Coll Surg. 2016; 222: 961-6.
• Ocampo D V, Gladman D. Psoriatic arthritis. F1000Res. 2019;8:F1000. Faculty Rev-1665.
• Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301-15.
• WHO. Global report on psoriasis. World Health Organization, Geneva 2016. Accessed date: 20 July 2022. Avaliable from: https://ifpa-pso.com/resources-tools/who-global-report-on-psoriasis
• Denis M. Tumor Necrosis Factor and Granulocyte Macrophage-Colony Stimulating Factor Stimulate Human Macrophages to Restrict Growth of Virulent Mycobacterium avium and to Kill Avirulent M. avium: Killing Effector Mechanism Depends on the Generation of Reactive Nitrogen Intermediates. J Leukoc Biol. 1991;49: 380-7.
• Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell. 1989;56(5):731-40.
• Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2003;48(11):3013-22.
• Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020;69(1):1-11.
• Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris- Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281-317.
• Mourik BC, Lubberts E, de Steenwinkel JEM, Ottenhoff THM, Leenen PJM. Interactions between type 1 interferons and the Th17 response in tuberculosis: lessons learned from autoimmune diseases. Front Immunol. 2017; 8: 294.
• Kammuller M, Tsai TF, Griffiths CEM, Kapoor N, Kolattukudy PE, Brees D, et al. Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clin Transl Immunol. 2017; 6: e152.
• Segueni N, Tritto E, Bourigault ML, Rose S, Erard F, Le Bert M, et al. Controlled Mycobacterium tuberculosis infection in mice under treatment with anti-IL-17A or IL-17F antibodies, in contrast to TNFa neutralization. Sci Rep. 2016; 6:36923.
• Ekici A, Alkan S, Aydemir S, Gurbuz E, Unlu AH. Trends in Naegleria fowleri global research: A bibliometric analysis study. Acta Trop. 2022; 234:106603.
• Alkan S, Evlice O. Bibliometric analysis of global gonorrhea research. Infectious Diseases & Tropical Medicine. 2022; 8: e876.
• Shuaib W, Khan MS, Shahid H, Valdes EA, Alweis R. Bibliometric analysis of the top 100 cited cardiovascular articles. Am J Cardiol. 2015;115(7):972-81.
• Şahin S. Research trends and top cited articles on the frozen elephant trunk procedure. Genel Tıp Dergisi. 2022; 32(6): 740-5.
• Pu QH, Lyu QJ, Su HY. Bibliometric analysis of scientific publications in transplantation journals from Mainland China, Japan, South Korea and Taiwan between 2006 and 2015. BMJ Open 2016;6: e011623
• Gökçe ON, Alkan S. Contribution of Turkey in Liver Transplant Research: A Scopus Database Search [published online ahead of print, 2022 May 23]. Exp Clin Transplant. 2022;10.6002/ect.2021.0491
• van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 2010;84(2):523-538. Doi: 10.1007/s11192-009-0146-3.
• Nafade V, Nash M, Huddart S, Pande T, Gebreselassie N, Lienhardt C, Pai M. A bibliometric analysis of tuberculosis research, 2007-2016. PLoS One. 2018;13(6):e0199706.
• World Health Organization. Global Tuberculosis Report 2017 [Internet]. Accessed date: 01 Nov 2022 Available from: http://apps.who.int/iris/bitstream /10665/259366/1/ 9789241565516-eng.pdf
• WHO global Tuberculosis Report 2022. Accessed date: 01 Nov 2022. Avaliable from https://www.who.int/teams/global-tuberculosis-programme/data